a once-weekly GLP-1 receptor agonist
0.25 MG → 2.4 MG · 4-week vial supply

Semaglutide is the first GLP-1 weight-management compound to enter wide clinical use. It is the active molecule in branded Wegovy® and Ozempic®. The HealthRX.com preparation is compounded by a licensed pharmacy under Section 503A on a valid, patient-specific prescription.
Semaglutide is a long-acting synthetic analog of human GLP-1, the gut hormone released after a meal. By binding to the GLP-1 receptor, it slows gastric emptying, amplifies the body's satiety signaling in the hypothalamus, and improves glucose-dependent insulin secretion. The result is reduced appetite, quieter food noise, and gradual sustained weight loss.
| Week | Dose | Note |
|---|---|---|
| Weeks 01–04 | 0.25 mg / week | Initiation. Lowest dose, designed to acclimate the gut. |
| Weeks 05–08 | 0.5 mg / week | First dose escalation. Most appetite changes start here. |
| Weeks 09–12 | 1.0 mg / week | Provider check-in. Re-evaluate tolerance and response. |
| Weeks 13–16 | 1.7 mg / week | Therapeutic dose for many patients. |
| Weeks 17+ | 2.4 mg / week | Maintenance dose, only if tolerated and clinically appropriate. |
Compounded semaglutide plans start at $99/mo with the annual option. The price you see at checkout is the price billed. No insurance required.
Semaglutide is the active molecule in branded Wegovy and Ozempic. The HealthRX.com preparation is compounded by a licensed 503A pharmacy on a valid, patient-specific prescription. It is not the branded product.
In the STEP-1 trial, adults lost an average of 14.9% of body weight at 68 weeks, and 86% lost at least 5% of body weight. Individual results vary and depend on dose, tolerance, and lifestyle.
Semaglutide is a once-weekly injection titrated from 0.25 mg up to a maintenance dose (up to 2.4 mg) over several months, escalated only as tolerated and clinically appropriate under provider supervision.
Semaglutide is not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN-2, a history of severe pancreatitis, or during pregnancy or breastfeeding. A licensed clinician reviews your history before prescribing.
Researching your options? Explore the full GLP-1 medicine library or compare compounded semaglutide and compounded tirzepatide.